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INTRODUCTION
The human genome comprises approximately 60 full-length HERV-K(HML-2) proviruses and about 2500 HERV-K solo long terminal repeats (LTR) (Gifford and Tristem, 2003; Mager and Medstrand, 2003) . The origin of these proviruses and LTR elements were retroviral infections of germ-line cells before and during primate evolution and subsequent amplification inside the host via retrotransposition, reinfection and complementation in trans.
As a consequence of mutations, deletions and internal homologous recombination most of these retroviral elements lost their replication capability and infectivity. But open reading frames and viral protein expression can still be found and there is accumulating evidence that HERVs play a direct role in tumor induction and progression as well as in physiological processes (Boese et al., 2000; Denne et al., 2007; Serafino et al., 2009; Denner, 2010) .
The family of HERV-K(HML-2) can be subdivided into type 1 and type 2 proviruses.
Type 1 proviruses are characterized by a 292 base pair (bp) deletion at the pol-env boundary and an open reading frame (ORF) for the nonstructural protein Np9 (Armbruester et al., 2002) . Type 2, the undeleted prototype, has an intact env sequence and encodes the accessory protein Rec (Lower et al., 1993 (Lower et al., , 1995 . Both proteins were found expressed in tumors and transformed cell lines and evidence has accumulated that they play a role in cancer development. Rec and Np9 directly bind to the promyelocytic leukemia zinc finger (PLZF) protein and inhibit the transcriptional inhibiting function of PLZF. As a result the MYC promoter loses its repressed state and MYC expression is promoting cellular proliferation (Denne et al., 2007) . In addition, mice that were transgenic for Rec showed a development of carcinoma in situ, an early marker for testicular cancer (Galli et al., 2005) . Expression of HERV-K(HML-2) mRNA and protein was found in germ cell tumors (Lower et al., 1984; Herbst et al., 1998) , in melanomas (Muster et al., 2003; Buscher et al., 2005 Buscher et al., , 2006 and in human breast carcinomas (Wang-Johanning et al., 2003) . A matter of particular interest is the expression of HERV-K(HML-2) in human melanomas. The presence of anti-HERV-K antibodies in early stages of the disease was shown to be a marker of reduced survival (Hahn et al., 2008) . Furthermore, HERV-K was reported to support the in vitro transition of melanoma cells from adherent to a more malignant, non-adherent phenotype when exposed to stress conditions (Serafino et al., 2009 ).
The regulation of HERV-K(HML-2) expression in melanomas is unclear. Besides transcriptional regulation via transcription factors (TFs) (Ono et al., 1987; Akopov et al., 1998; Knossl et al., 1999; Kwun et al., 2002) , an epigenetic regulation via DNA-methylation was reported in teratocarcinomas (Gotzinger et al., 1996) . A correlation between methylation of the U3 region of the HERV-K(HML-2) 5'LTR and the transcriptional activity of the LTR was shown (Lavie et al., 2005) .
To understand the high transcriptional activity of HERV-K(HML-2) proviruses in melanomas and to demonstrate their cancer specific expression, we investigated the regulation of these retroviral elements in more detail. A panel of human melanoma cell lines was analyzed for HERV-K-expression, promoter activity and the methylation status of the 5'LTR.
Based on these data it was shown that cells with high HERV-K-expression compared to cells with basal levels of HERV-K mRNA exhibited genetic and epigenetic changes. High levels of HERV-K expression were only found in melanoma cell lines that also showed a high HERV-K promotor activity. In addition, those cell lines exhibited low levels of LTR methylation. In line with this cell lines not expressing HERV-K showed stronger methylation of 5'LTRs and expression could be stimulated by treatment with the demethylating agens 5-aza-dC.
Therefore, melanoma cell lines that showed high levels of HERV-K expression must have lost methylation and, in addition, a deregulation of HERV-K specific TFs must have occurred.
MATERIALS AND METHODS

Cell Lines and Treatments
The SK-MEL-13 and SK-MEL-19 melanoma cell lines were obtained from Dr.
J. Eberle (Department of Dermatology, Charité-Universitätsmedizin, Campus Benjamin Franklin, Berlin, Germany), and the SK-MEL-24 and SK-MEL-37 were a gift from Dr. Peter Walden (Department of Dermatology, Charité Campus Mitte, Berlin, Germany). The cell lines were cultured as described previously (Bredenbeck et al., 2005; Fecker et al., 2005) . The human melanoma cell lines SK-MEL-28, SchM, SchW, TR, ZO, KU, RA, and ZD, the human embryonic kidney cell line 293, the human teratocarcinoma cell line GH and the isolation of PBMCs have been described previously (Buscher et al., 2005) . HEK-293 and melanoma cell lines were treated with 2 µM 5-aza-dC (Sigma Aldrich, Germany) and 50 nM trichostatin A (Sigma Aldrich) and GH cells with 1 µM 5-aza-dC and 25 nM trichostatin A. The drug containing medium was renewed every day and cells were harvested after 3 days of treatment.
RNA and DNA Preparation
Total RNA and genomic DNA from cell cultures were isolated using RNeasy and DNeasy Kits, respectively, according to manufacturer's instructions (Qiagen, Hilden, Germany). Quality and quantity of both RNA and DNA were determined by 1% agarose gels and photometry.
Quantitative Real-Time RT-PCR 500 -2000 ng of total RNA were reverse transcribed using the RevertAid™ H Minus M-MuLV Reverse Transcriptase Kit (Fermentas, St. Leon-Rot, Germany) and Random Hexamer Primer according to manufacturer's protocols. Then the reaction products were diluted 1:10 and 1µl was used for performing quantitative real-time PCR using the Brilliant SYBR® Green QPCR Master Mix and the Mx4000® QPCR System (Stratagene, Germany).
For detection of HERV-K(HML-2) env mRNA the primer pair Pfor/Penv, for detection of the rec mRNA the primer pair Pfor/Prec and for detection of np9 mRNA the primer pair Pfor/Pnp9 was used. Within each experiment the housekeeping gene GUSB was used for data normalization (for primer sequences see supplemental material Table 1 ).
HERV-K108 LTR Luciferase Promoter Reporter Construct
The 5'LTR reporter construct was generated by cloning a PCR fragment starting at position -283 bp upstream of the 5'LTR of HERV-K provirus K108 until position +1255 bp.
Following PCR, amplicons were subcloned into the luciferase vector pGL3-Basic (Promega, Mannheim, Germany) and subclones were verified by DNA sequencing.
Dual Luciferase Reporter Gene Assay
Luciferase activity was measured after transient transfection of the pGL3 basic vector In Vitro DNA Methylation. 
Methylation Analysis by Genomic Sequencing
Sodium bisulfite treatment was performed as previously described (Frommer et al., 1992) . Locus-specific nested PCR was performed using primer pairs BSS-K108-183fw/BSSK108+1306rev and BSS-K108-40fw/BSS-K108+1121rev under conditions described elsewhere (Schenk et al., 2007) . PCR amplification was performed for 32 cycles of 30 sec at 95°C, 20 sec at 55°C and 200 sec at 72°C. The second amplification step was carried out using 1/100 of the first PCR product for 32 cycles of 30 sec at 95°C, 20 sec at 55°C and 180 sec at 72°C. Then the PCR-fragments were subcloned into a TA-Cloning vector.
Transformation into E.coli Top10 F' competent cells was performed with CaCl 2 . Plasmid DNA was prepared from transformed clones and sequenced using M13-promotor-primers and the ABI BigDye 3.1-Mastermix (ABI Terminator Chemie, Applied Biosystems, Darmstadt, Germany).
Methylation Analysis by Methylation Sensitive Restriction Endonucleases
200 ng of genomic DNA from each cell line were digested over night in 30 µl reaction volume using the methylation sensitive endonucleases HpaII, BsaAI (New England Biolabs) and TauI sec at 60°C and 60 sec at 72°C. The PCR reaction was then analyzed using agarose gel electrophoresis and DNA staining with ethidium bromide.
To verify the existence of HpaII restriction sites, digestion was performed using the methylation insensitive HpaII isochizomer MspI. Due to the absence of methylation insensitive isochizomers for the restriction enzymes BsaAI and TauI, the verification of the presence of specific restriction sites for those enzymes was performed using PCR products of the investigated HERV-K proviruses as substrates for digestion.
To verify the assay, the 5'LTR of HERV-K 22q11 was subcloned into a TA-Cloning vector and in vitro methylation was performed by SssI DNA methyltransferase as described above. The differentially methylated vector was used for digestion and PCR-amplification as also described above.
RESULTS
High Levels of Spliced HERV-K mRNA in Human Melanoma Cell Lines
In order to analyze HERV-K expression in a panel of melanoma cell lines comprising the previously analyzed cell lines SK-MEL-28, RA, TR, SchM, SchW and ZD (Buscher et al., 2005; method (Livak and Schmittgen, 2001) in comparison with the HERV-K expression in the teratocarcinoma cell line GH known to express HERV-K mRNAs at a very high level (Buscher et al., 2005) . Five of the eleven cell lines showed high levels of HERV-K env and rec mRNA expression (Fig. 1A) . These cell lines also showed increased (but not high) levels of np9 mRNA (0.2% of the expression in GH cells) (Fig. 1A) . to the other cell lines) showed nearly the same luciferase activity, when the pGL3b-control vector was used, indicating nearly equal transcriptional activities (Fig. 1B) . When a luciferase expression vector was used, which contained a HERV-K 5'LTR as a promoter, all cell lines with high HERV-K expression showed a significant higher luciferase activity than cell lines with only a basal level of HERV-K transcription, indicating that HERV-K-expressing cell lines had a different level of activated HERV-K-specific TFs compared to cell lines not expressing HERV-K (Fig. 1B) . These results raised the question whether high HERV-K LTR activities were typical for melanomas or whether only a few tumor cell lines express sufficient TFs able to activate HERV-K LTRs. To answer this question a set of another ten melanoma cell lines was randomly selected without knowing their level of HERV-K mRNA expression.
These cell lines were investigated for LTR activity as shown above. In none of the ten cell lines was high LTR activity detected (Fig. 1C) , suggesting that high HERV-K LTR activity is not a general property of melanoma cells but may be the result of disturbed regulation during tumor progression.
The LTR Activity in Melanoma Cell Lines Depends Directly on the CpG
Methylation Status of the 5'LTR.
As mentioned above, regulation of gene transcription depends not only on the availability of activated TFs but is also regulated by the accessibility of the activated TFs and the RNAP II to the promoter. It had been shown previously that the promoter activity of HERV-K(HML-2) 5'LTRs was reduced after CpG methylation in the teratocarcinoma cell line Tera-1 (Lavie et al., 2005) . These data raised the question whether methylation also plays an important role in HERV-K silencing in melanoma. To answer this question, the HERV-K LTR-driven reporter gene construct pGL3-LTR was methylated in vitro using the CpG methyltransferase SssI (Fig. 2A) . Using increasing amounts of methyltransferase higher levels of methylation were achieved. After transient transfection of these constructs into cell lines expressing HERV-K, all analyzed cell lines showed a loss of promoter activity dependent on the level of CpG-dinucleotide methylation. Cells that were transfected with plasmids showing nearly full methylation exhibited only basal levels of luciferase expression comparable with the LTR activity measured in cell lines not expressing HERV-K (Fig. 2B ). These findings indicated that the assembly of TFs and the RNAP II on the HERV-K(HML-2) 5'LTR is directly or indirectly inhibited by CpG-methylation in melanomas.
Cell Lines Expressing HERV-K Showed a Lower LTR Methylation Level than Cell Lines With Low HERV-K Expression
To analyze the methylation status of different HERV-K 5'LTRs in melanoma cell lines a methylation detection assay was established using three methylation sensitive restriction enzymes (see Materials and methods and supplemental Fig. 1A) . To validate the assay, plasmids that contained the 5'LTR of HERV-K 22q11 methylated at increasing levels were used as a substitute of genomic DNA. Digestion of the plasmid DNA by the restriction enzymes HpaII and BsaAI showed that strong and intermediately methylated sites could be detected. Using TauI for restriction only strong CpG methylation could be seen (supplemental Fig. 1 B) . For a comprehensive analysis of the methylation status of HERV-K-5'LTRs in melanoma cell lines, specific primers for ten proviruses and two solo LTRs were designed. both not expressing HERV-K, showed nearly total methylation of the investigated sequence (Fig. 3) , strong demethylation was detected in the teratocarcinoma cell line GH. In this cell line methylation was only observed at single CpG sites in the U5 region and the 5'UTR.
Whereas in cell lines expressing HERV-K demethylation of HERV-K-108 was observed in the whole investigated sequence (except SK-MEL-28 that showed some methylation of the last CpG-dinucleotides in the 5'UTR), cell lines with low levels of HERV-K mRNA showed stronger methylation of the U5 region and the 5'UTR. All melanoma cell lines not expressing HERV-K also showed demethylation in U3 and the starting R-region (Fig. 3) . These data confirm differences in methylation of HERV-K(HML-2) 5'LTRs between cell lines expressing or not expressing HERV-K and that methylation negatively correlates with HERV-K expression.
5-aza-dC Stimulates HERV-K Expression in Melanoma Cell Lines.
To demonstrate that CpG methylation is an epigenetic silencer of HERV-K transcription in melanoma cell lines, control and melanoma cell lines were treated with the demethylating agent 5-aza-dC. After treatment, changes in HERV-K expression were measured by quantitative real-time RT-PCR using primers for env, rec and np9. Thereby, treatment of GH cells with 5-aza-dC resulted in a slight increase of expression of these genes (Fig. 4A) . In contrast, a very strong increase of HERV-K env and rec and a slight increase of np9 expression were detected in HEK-293 cells (Fig. 4B) , in which HERV-K is normally not expressed. Similar results were obtained when treating melanoma cell lines. In the HERV-K-expressing melanoma cell lines SK-MEL-13 and SK-MEL-19 no changes in HERV-K expression were observed after treatment with 5-aza-dC (with exception of a small increase of np9 mRNA in SK-MEL-13). On the other hand, melanoma cell lines with a low level of HERV-K expression showed a significant increase in the levels of env, rec and np9 mRNA.
This increase was also measured in the cell line RA but it was not as strong as in cell lines, which do not express HERV-K. This finding correlates with the low promoter activity shown in RA cells. In contrast, a clear increase of HERV-K env and rec but not np9 expression was observed after treatment of the cell line SchM, which highly expressed HERV-K. But, as
shown above, the cell line SchM exhibited a much stronger LTR methylation in comparison with SK-MEL-13 (Table 1 ). In addition to DNA methylation, initiation of HERV-K transcription may also be regulated by complex modifications of histone molecules. Thereby acetylation of histones results in open and transcriptionally active chromatin. In order to investigate the influence of histone acetylation on the transcriptional activity of HERV-K(HML-2), melanoma cell lines were treated with the histone deacetylase inhibitor TSA.
Only HEK-293 cells exhibited increased HERV-K-expression as a result of TSA treatment.
Co-treatment of HEK-293 cells with 5-aza-dC and TSA showed a synergistic effect on the expression of env, rec and np9. Such effects were not observed when melanoma cell lines were treated, indicating that transcriptional regulation by histone acetylation may not be a key regulatory element in HERV-K expression.
5-aza-dC Does not Increase the Level of LTR Activating TFs.
The activation of HERV-K-expression by 5-aza-dC in cell lines with low expression of HERV-K may be due to the global demethylation of the genome and therefore due to the activation of HERV-K specific TFs or due to the demethylation of HERV-K-5'LTRs. To discriminate between both possibilities an indirect analysis was performed using transient transfection of an unmethylated LTR reporter gene construct followed by 5-aza-dC treatment.
In parallel, untransfected cells were treated with the same medium that was used for treatment of the transfected cells (containing 5-aza-dC or not). All cell lines treated with 5-aza-dC showed an increase of rec expression in comparison to untreated controls indicating a successful treatment with 5-aza-dC (Fig. 5B) . In contrast to that, no significant changes in LTR activity was observed as measured by luciferase activity. The cell line SK-MEL-37 exhibited a slight increase in LTR activity after 5-aza-dC treatment by a factor of two (Fig.   5A ), which cannot reflect the increase of HERV-K-expression measured by real-time PCR (twelvefold).
DISCUSSION
The overall prognosis of patients with advanced melanoma is very poor due to the lack of effective treatment and late detection of the tumor. Therefore reliably detection methods and meaningful tumor markers are required (Riker et al., 2007) . One important requirement for high levels of HERV-K(HML-2) expression in melanomas is a high promoter activity. This conclusion is based on two observations. First, none of the melanoma cell lines with a low HERV-K mRNA level showed a high luciferase expression after transfection with the unmethylated HERV-K LTR reporter gene construct.
Second, none of the randomly chosen melanoma cell lines showed a strong luciferase activity after luciferase HERV-K LTR plasmid transfection -both indicating low levels of HERV-Kspecific TFs in those cell lines. Therefore high promoter activities as found in cell lines with high levels of HERV-K mRNA (Fig. 1A) are most likely the result of increased activation of HERV-K specific TFs. Strong LTR activity in melanomas may be the result of higher expression of the HERV-K activating TFs YY1 (Knossl et al., 1999) or AP1 (Kwun et al., 2002) . Interestingly, there are higher levels of YY1 mRNA in SK-MEL-28 cells compared with normal skin (Su et al., 2004) .
In addition to a transcriptional regulation via TFs there is an epigenetic regulation by CpG-dinucleotide methylation (Lavie et al., 2005) . Endogenous LTR elements are usually transcriptionally silenced by CpG methylation in somatic cells (Bestor, 2000) and strong DNA methylation was reported in fetal brain, fetal liver, placenta and adult peripheral leukocytes (Shen et al., 2006) . In melanomas, HERV-K promoter activity depends directly on the methylation status of its 5'LTR (Fig. 2) . This suggests that HERV-K activating TFs are sensitive to CpG methylation. For example it is known that the HERV-K activating transcription factor YY1 does not bind methylated DNA in vitro (Kim et al., 2003) .
Interestingly, demethylation of one or more HERV-K-5'LTRs was found in every cell line tested, but in cells with high HERV-K expression less methylation was observed than in cells with only a basal level of HERV-K expression, supporting the hypothesis of a methylation dependent regulation of HERV-K proviruses in melanoma. Especially in the cell lines GH and SK-MEL-13 with the highest HERV-K expression (Fig. 1A) , demethylation was found for nearly every tested 5'LTR indicating genome wide demethylation of HERV-K 5'LTRs. This is in line with the finding that these cell lines did not show an additional HERV-K activation after treatment with the demethylating agent 5-aza-dC. The reason for global demethylation in those cell lines could be a loss of maintaining methylation by the DNA methyltransferase-1 (DNMT1) (Bestor, 2000; Howard et al., 2008) . The loss of maintaining DNA methylation and genome wide demethylation could have driven tumor progression by activation of oncogenes or chromosomal destabilization (Howard et al., 2008; Daskalos et al., 2009) This suggests that these regions may contain methylation dependent regulatory elements.
Although most of the analyzes were performed using melanoma cell lines that may not reflect the entire in vivo situation in the primary tumor, in preliminary investigations a comparable high level of HERV-K expression was found in primary melanomas using real time PCR (data not shown). This indicates that the situation of HERV-K expression in melanoma cell lines is comparable to that in melanoma.
To summarize, high levels of HERV-K mRNA expression in melanomas are the result of two processes, namely upregulation of HERV-K activating TFs and a defect in maintaining LTR methylation. Both processes must occur in melanoma cells in order to induce a strong HERV-K(HML-2) expression, as seen for example in germ cell tumors. Therefore, high levels of HERV-K expression in melanomas might be a marker for genetical and epigenetical changes.
Demethylation is obviously necessary for the expression of HERV-K. Since it is unlikely that HERV-K is able to demethylate its proviruses, the loss of methylation must be the result of genetic changes in the cell, e.g., a loss of DNMT1 activity. Therefore, the activation of HERV-K expression ought to be understood as a secondary event. The increase in demethylation may enhance expression of HERV-K mRNA as well as Env, Rec and Np9
proteins. Since there is preliminary evidence that Rec and Np9 may be involved in tumorigenesis (Galli et al., 2005) , they may contribute to tumor induction. In addition, the expression of the immunosuppressive Env protein may contribute to tumor progression preventing tumor rejection by the immune system (Mangeney and Heidmann, 1998; Mangeney et al., 2001 Mangeney et al., , 2005 Denner, 2010) . In this context it is of great interest whether HERV-K proteins are good targets for cancer immunotherapy. Such investigations will help to understand the role of HERV-K proteins, if any, in the development of melanomas.
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